Vertex Pharmaceuticals Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VX1.F | 095700.KQ | KRYS | ROIV | 1530.HK | BBIO | |
|---|---|---|---|---|---|---|
| Market cap | 122.76B | 94.14B | 9.21B | 27.61B | 37.99B | 15.17B |
| P/E (TTM) | 36.9 | — | 42.2 | — | 4.1 | — |
| Forward P/E | 36.9 | — | 34.0 | -27.5 | 11.2 | -225.0 |
| Price/book | 6.6 | — | 6.4 | 6.5 | 1.2 | -5.9 |
| Dividend yield | — | — | — | — | 1.69% | — |
| 1-year change | +30.10% | −60.56% | +52.61% | +85.85% | −51.32% | +24.17% |
| Today | −0.51% | +0.73% | +1.90% | +6.08% | +4.00% | +5.21% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All VX1.F news ›Vertex Pharmaceuticals Reaches $558.88, a Fresh 52-Week Peak
As seen on the 24/7 Wall St. homepage on October 30, 2026. Vertex Pharmaceuticals closed at $558.88, a fresh 52-week high and 0.16% above the September 3 peak. The $141.7 billion biotech has now reclaimed the top of its range after a…
Reviewing BioLineRx (NASDAQ:BLRX) and Vertex Pharmaceuticals (NASDAQ:VRTX)
Posted by Danessa Lincoln on Oct 30th, 2026 BioLineRx (NASDAQ:BLRX – Get Free Report) and Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two…
UK Healthcare Regulator OKs Vertex Pharmaceuticals' Casgevy Gene Therapy for Children From Age Five
... UK Healthcare Regulator OKs Vertex Pharmaceuticals' Casgevy Gene Therapy for Children From Age Five Published on 10/30/2026 at 05:30 am EDT
Vertex Pharmaceuticals Says UK Approves Casgevy for Children Aged 5 and Older
Vertex Pharmaceuticals received approval from the UK's Medicines and Healthcare products Regulatory Agency, or MHRA, to use Casgevy for children aged five and older with severe sickle-cell disease... Vertex Pharmaceuticals Says UK Approves…
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Oxford BioMedica (OXBDF)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Oxford BioMedica (OXBDF) with bullish sentiments. In a report released today, Phil Nadeau from TD Cowen…
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
It secured Food and Drug Administration (FDA) approval for an IMDELLTRA label update, and the Federal Trade Commission filed an amicus brief in a lawsuit concerning its Enbrel patents. It finalized the acquisition of Crinetics…
Vertex Pharmaceuticals VRTX Drops 4.1%, Shedding ~$5 Billion in One Session
As seen on the 24/7 Wall St. homepage on October 13, 2026. A 4.1% drop to $486.60 lops roughly $5 billion off a $123.3 billion biotech in a single session, a rare one-day swing for a name that usually trades like a defensive compounder.…
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Mineralys Therapeutics, Inc. (MLYS)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Mineralys Therapeutics, Inc. (MLYS) with bullish sentiments. BMO Capital analyst Evan Seigerman maintained a…
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.
Vertex Pharmaceuticals' (VRTX -2.10%) stable of cystic fibrosis (CF) therapies is one of the biggest monopolies among biotech companies. The company was founded in 1989 and, after dabbling in infectious diseases, struck gold when it…
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) American Society of Nephrology (ASN) Kidney Week 2026 October 23, 2026 8:15 PM EDTCompany ParticipantsSusie Lisa... Vertex Pharmaceuticals Incorporated (VRTX) American Society of Nephrology (ASN)…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com16
- fool.com7
- theglobeandmail.com6
- themarketsdaily.com3
- 247wallst.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 55 articles, not a forecast.